Miraculins closes $400,000 private placement:
This article was originally published in Clinica
Canadian cancer biomarker specialist Miraculins has raised $428,000 from the private placement of approximately 1.2 million units of company stock at a price of $0.35 per unit. Each unit comprised of one common share and half a share purchase warrant. One whole warrant enables the holder to purchase a Miraculins share at $0.65 per share for the twelve-month period after the issuing of the unit. Winnipeg, Manitoba-based Miraculins said the proceeds would be used for R&D and working capital purposes. The company's main focus is on biomarker discovery using its BEST Platform, for screening and identifying target proteins and peptides related to diseases.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.